<DOC>
	<DOCNO>NCT01077128</DOCNO>
	<brief_summary>Primary objective - To evaluate quality life Adalimumab treat patient period 12 month Secondary objective - To evaluate long-term efficacy Adalimumab patient moderate severe chronic plaque psoriasis prescribed dermatologists day-to-day clinical practice accordance term European marketing authorization . - To evaluate change patient quality life accord treatment response 12-month period - To observe assess long term use safety Adalimumab prescribe dermatologist normal clinical set accordance term European marketing authorization .</brief_summary>
	<brief_title>Greek Study Quality Life Patients With Psoriasis Treated With Adalimumab</brief_title>
	<detailed_description>The aim post-marketing observational study adult patient moderate severe chronic plaque psoriasis obtain data patient 's Quality Life assess impact Adalimumab treatment patient 's quality life condition day-to-day clinical practice Greece . This study ass relationship clinical outcome patient-reported outcome . As observational study , Abbott provide study drug . Humira prescribe accord routine medical practice . The participate physician free determine appropriate therapy patient make treatment choice deem clinically necessary . The Dermatology Life Quality Index ( DLQI ) use assess patient quality life . The Dermatology Life Quality Index ( DLQI ) total score range 0 30 , 0 correspond best quality life 30 bad . The Dermatology Life Quality Index ( DLQI ) well-established reliability validity determine several study . Moreover , frequently use clinical trial psoriasis . The physician 's global assessment disease severity ( PGA ) use measure patient ' disease status time assessment . It 6-point scale measure degree overall psoriatic lesion severity , score range 0 ( clear ) 5 ( severe ) . Complementary , European Quality Life-5 Dimensions health questionnaire ( EQ5D ) use measure health outcome . This applicable wide range health condition treatment provide simple descriptive profile single index value health status . Health economic data collect use European Quality Life-5 Dimensions health questionnaire ( EQ5D ) questionnaire data regard patient hospitalisation due psoriasis . Hospitalisation data collect 6 month period throughout observation period . Moreover , study observe current medical practice prescribe Adalimumab Greece detail data prescription behavior collect . Guidelines develop order ensure new class therapy ( biologic agent ) introduce systematic planned way achieve great possible benefit people psoriasis facilitate safe effective prescribing . However , many issue fully address , recommendation regard amount time wash previous antipsoriatic drug combination therapy . Such issue remain discretion healthcare professional . Since observational study patient treat accordance physician 's usual customary medical practice . Thus , follow information regard use Adalimumab collect - previous systemic treatment history record include previous biological therapy patient receive , , - wash period prior initiate Adalimumab therapy , - reason stop previous treatment , - combination Adalimumab topical systemic antipsoriatic agent , applicable Furthermore , demographic data patient suffer psoriasis Greece collect ( age , gender , ethnicity ) disease data duration disease , involvement nail joint , geographic distribution disease Greece collect .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients moderate severe chronic plaque psoriasis newly prescribe Humira ( adalimumab ) therapy ( never treat adalimumab ) treat physician make decision eligible treatment adalimumab accordance term local marketing authorization Patients moderate severe chronic plaque psoriasis Adalimumab indicate prescribed accord current approved local SPC long first administration adalimumab old two month dose interruption since initiation adalimumab , Investigator provide need source documentation include complete DLQI questionnaire start Adalimumab treatment . Patient age â‰¥ 18 Patient willing consent data collect provided Abbott Patients meet contraindication outline late version local approve SPC Patients participate another clinical/observational study Patients willing sign Informed Consent Form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Quality life</keyword>
</DOC>